# Pizarra — PT-pseudo_0615b2bd8504 (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_0615b2bd8504
Task: 1

Encounter: Urology - outpatient on 26 Jan 2025.
Referrer: Dr. C. Peters (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 63-year-old male
  - PSA: 160.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 2.635 ng/mL²
  - PSA velocity: 35.73 ng/mL/yr
  - Prior PSA: 115.9 ng/mL
  - Prostate volume: 60.71 mL
  - Months since last PSA: 1
  - DRE findings: Abnormal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.95889634 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 160 ng/mL. PI-RADS 5. PSAD 2.63. Prostate volume 61 mL. DRE abnormal. csPCa 0.96.

Vitals: weight 93 kg, height 191 cm, BMI 25.5, BP 140/81 mmHg, HR 48 bpm. Smoking: Current smoker (20 pack-yr).

Chief complaint: Persistent elevation in PSA levels alongside a history of biopsy-confirmed prostate adenocarcinoma warrants clinical reassessment.

History: Now aged 63-year-old, the individual works as a retired bank clerk and Lives in ground-floor apartment with partner. Following an initial PSA measurement of 55.0 ng/mL in late 2022, a prior biopsy bucket "Positive" was documented. He maintains a Married status and engages in light resistance training twice weekly, complemented by a moderate alcohol intake of 14 units per week. Current smoker (20 pack-yr) status is noted, though he explicitly denies haematuria, pelvic discomfort, or lower urinary tract symptoms exceeding a baseline IPSS of 10. Past medical reviews include a routine hearing evaluation, an orthopaedic check for stable knee osteoarthritis, and a memory clinic assessment revealing intact cognition. He has never utilized 5-alpha-reductase inhibitors. General health remains excellent with an ECOG performance status of 0. Comorbidities: none. Active medication: None.

Physical examination: DRE — texture: firm and irregular nodule palpable in the left posterior peripheral zone; mobility: fixed; asymmetry: pronounced enlargement with right lobe induration but no distinct discrete masses; overall classification: cT3a. Abnormal DRE confirmed. Vital signs record a blood pressure of 140/81 mmHg and a resting heart rate of 48 bpm. General survey shows no palpable lymphadenopathy or hepatosplenomegaly.

Patient info: retired bank clerk; Married; Lives in ground-floor apartment with partner.
Next of kin: Sibling (brother).

Lifestyle: alcohol 14 units / week; exercise Light weight-training at home, 2x/week; IPSS score: 10/35 (moderate LUTS).

Recent other appointments: Audiology — hearing test; Orthopaedic outpatient — knee follow-up; Memory clinic — baseline screening.
Admin: Patient self-employed; flexible appointment slots requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: NO BIOPSY
  p(biopsy = yes) = 0.45 +/- 0.27   (95% CI 0.02-0.94)

Where the uncertainty comes from:
  - aleatoric  dA = 0.26  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.06  (few labelled cases resemble this one)
  - 0.6 effective neighbours out of 10; 1 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {no}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=5.0, bx_ord=3.0, psa=160.0, age=63.0, psad=2.635, dre_ord=2.0, vol=60.71, n_pmhx=0.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior positive biopsy.

THIS CRITERION RETURNS NO ANSWER FOR THIS PATIENT.

The criterion: The visible panel does NOT determine this decision. The patient already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. The decision must come from the retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed.

Measured on the 49 labelled cases with a prior positive biopsy: no structured variable separates the two answers (PSA is rising in all 49), the split is 26 defer / 23 biopsy, and every rule fitted on one half of the data failed on the other. This is genuinely undetermined by the panel.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle the case and the retrieved documents must.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only considered the visible panel data (PI-RADS=5, PSA=160.0, prior biopsy Positive, csPCa probability=0.95889634) and failed to incorporate the PSA velocity (35.73 ng/mL/yr), the PSA history (prior PSA 115.9 ng/mL), the PSA density (2.635 ng/mL²), and the DRE findings (Abnormal/Nodule).

WHY THE SUGGESTION COULD BE WRONG
The prior suggested NO BIOPSY with a wide uncertainty interval (0.45 +/- 0.27). This wide interval indicates the classifier cannot distinguish between the two outcomes, suggesting the panel is insufficient. Furthermore, the prior ignores the guideline criterion that states the decision must rely on retrieved documents, which the prior explicitly failed to do.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - does the lesion compare with a previous MRI? - if it is unchanged the case for sampling weakens; if new or larger it strengthens
PSA history - to assess the trend beyond the headline value
previous GP / urology notes - to see if prior biopsy grade is documented
laboratory panel - to see if PSA density is used in risk stratification
family-history anamnesis - to check for genetic risk factors
The retrieval of the MRI report is critical as the guideline mentions that a stable MRI (PRECISE 1-3) might exclude repeat biopsy.

GUIDELINE ANCHOR
The guideline states that the decision must come from retrieved documents, specifically whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed.

## [5] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
{"case_id": "PT-pseudo_0615b2bd8504", "radiology_report": "Subject: Prostate Multiparametric MRI | Date: 20 January 2025 | Facility: Amsterdam UMC (AMC)\nIndication: Rising PSA (160.0 ng/mL) alongside a previously positive biopsy history.\nFINDINGS:\nProstatic dimensions yield a total volume of 60.71 mL. A discrete abnormality resides in the left peripheral zone, spanning roughly 35 mm at its widest point. Imaging characteristics include pronounced T2 hypointensity, marked diffusion restriction paired with depressed ADC values, and prompt contrast uptake on dynamic sequences. Suspicion for extracapsular extension centers on the left posterolateral margin.\nIMPRESSION:\nPI-RADS 5 lesion in the left peripheral zone with suspected extracapsular extension. PSAD 2.635 ng/mL/mL. csPCa predicted probability 0.95889634"}
get_psa_trend
{"case_id": "PT-pseudo_0615b2bd8504", "psa_trend": [{"date": "Aug 2022", "val": 14.8}, {"date": "Jun 2023", "val": 18.9}, {"date": "Apr 2024", "val": 12.0}, {"date": "Jan 2025", "val": 160.0}]}
get_previous_notes
{"case_id": "PT-pseudo_0615b2bd8504", "previous_notes": [{"date": "31 May 2024", "author": "Dr. C. Peters (GP)", "text": "Initial screening captured a PSA reading of 55.0 ng/mL, while the contemporaneous digital rectal assessment showed no abnormalities. Subsequent transrectal ultrasound guidance yielded a biopsy confirming Gleason 3+4 pathology. The clinical record was then submitted to the urology department for case review."}, {"date": "06 Feb 2023", "author": "Dr. C. Peters (GP)", "text": "Subsequent tracking shows the PSA level climbing to 115.9 ng/mL. The individual reports consistent urinary complaints quantified at an IPSS of 10, with no episodes of acute retention or visible blood in the urine. Due to the accelerated PSA trajectory and established histology, an expedited outpatient urology visit was scheduled for advanced imaging and procedural planning."}]}
get_lab_results
{"case_id": "PT-pseudo_0615b2bd8504", "laboratory_results": [{"name": "PSA", "val": "160.0 ng/mL", "date": "11 Jan 2025", "flag": "H"}, {"name": "Free PSA", "val": "16.71 ng/mL", "date": "11 Jan 2025", "flag": ""}, {"name": "%Free PSA", "val": "10%", "date": "11 Jan 2025", "flag": "L"}, {"name": "Haemoglobin", "val": "13.2 g/dL", "date": "11 Jan 2025", "flag": ""}, {"name": "WBC", "val": "4.7 x10^9/L", "date": "11 Jan 2025", "flag": ""}, {"name": "Platelets", "val": "163 x10^9/L", "date": "11 Jan 2025", "flag": ""}, {"name": "Creatinine", "val": "72 umol/L", "date": "11 Jan 2025", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "11 Jan 2025", "flag": ""}, {"name": "Testosterone", "val": "11.7 nmol/L", "date": "11 Jan 2025", "flag": ""}, {"name": "Alkaline phosphatase", "val": "55 U/L", "date": "11 Jan 2025", "flag": ""}, {"name": "LDH", "val": "185 U/L", "date": "11 Jan 2025", "flag": ""}]}

NOT RETRIEVED
The family-history anamnesis was not retrieved, which could potentially provide genetic risk context.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- MRI report: PI-RADS 5 lesion with suspected extracapsular extension.
- PSA trend: Significant rise from 12.0 ng/mL (Apr 2024) to 160.0 ng/mL (Jan 2025).
- Previous notes: Prior biopsy confirmed Gleason 3+4 pathology, and a prior expedited visit was scheduled.

AGAINST sampling this patient now:
- MRI report: Lesion is described as a PI-RADS 5, but the report notes "Suspicion for extracapsular extension," which is not a definitive finding for immediate biopsy indication.

WHERE THIS LEANS
The evidence strongly points toward sampling due to the high-risk MRI finding (PI-RADS 5 with suspected extension) and the significant, rapid rise in PSA, which overrides the guideline's ambiguity for a prior positive biopsy.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [6] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [7] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: borderline)

Although the patient has a prior positive biopsy, the evidence strongly supports proceeding with a new biopsy due to the high-risk PI-RADS 5 finding with suspected extracapsular extension and the significant PSA velocity of 35.73 ng/mL/yr. The PSA level of 160.0 ng/mL is also highly concerning, and the previous notes confirm a prior Gleason 3+4 diagnosis without documentation of a current staging pathway. The retrieved MRI report's suspicion for extracapsular extension provides a strong indication that further tissue sampling is necessary to guide definitive treatment planning.

Variables that carried weight: bx=important, age=important, dre=important, psa=decisive, vol=noted, psad=important, pirads=important, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
